Sociedad Americana de Hirudoterapia

Bloodletting therapy using subcutaneous heparin and controlled scarification for venous insufficiency in free flap reconstruction

Microsurgical technique published in Microsurgery (2025)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportEnsayos clínicosDesarrollo de fármacosYalcin CE · Microsurgery, 2025

Abstract

BACKGROUND: Venous congestion is a significant complication in microsurgical reconstruction and may persist despite surgical revision attempts, as demonstrated in our clinical experience. In cases where repeated surgical interventions are either not feasible or unsuccessful, alternative methods like bloodletting therapy using subcutaneous heparin injection may be beneficial. METHODS: This descriptive, retrospective report evaluated six patients who underwent microsurgical tissue transfers between 2019 and 2025 and developed refractory venous congestion. Patients were managed with a standardized protocol involving a single subcutaneous injection of 10 IU heparin administered into the congested flap zone at initiation. Dermal windows measuring approximately 2 × 5 mm were created and during follow-up, heparin-soaked gauze pads (1000 IU heparin in sterile saline) were applied over the dermal windows to sustain bleeding. If bleeding diminished, windows were gently enlarged or new sites were created. RESULTS: The mean age of the six patients was 30.8 years (range 12-63). Total flap survival was achieved in three patients (50%), partial loss in two patients (33%), and marginal loss in one patient (17%). Treatment duration ranged from 3 to 10 days, with a mean transfusion requirement of 1.8 units per patient (Range 0-6 units). CONCLUSION: Subcutaneous heparin combined with controlled scarification represents a safe, practical, and potentially effective method to manage persistent venous congestion when surgical revision is unsuccessful or contraindicated. Future prospective studies are warranted to better define its role and optimize outcomes.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansHeparinRetrospective StudiesMiddle AgedMaleAdultFemaleFree Tissue FlapsVenous InsufficiencyPlastic Surgery ProceduresAdolescentYoung Adult

Resumen

Describes modern chemical bloodletting using subcutaneous heparin plus controlled scarification as MLT alternative for venous insufficiency in free flaps — useful when leeches unavailable.

Por qué esto importa para la hirudoterapia

Este informe retrospectivo describe a seis pacientes con congestión venosa refractaria tras reconstrucción microquirúrgica con colgajo libre que fueron tratados con inyección subcutánea de heparina a dosis bajas y escarificación controlada (ventanas dérmicas con gasa impregnada en heparina), logrando la supervivencia total del colgajo en el 50% de los pacientes. El enfoque es conceptualmente análogo a la terapia con sanguijuelas medicinales para la congestión venosa, representando una alternativa farmacológico-mecánica. Para el ámbito de la ASH, la relevancia es indirecta: el estudio no emplea sanguijuelas, secretoma de sanguijuela ni hirudina, e involucra una serie de casos pequeña (n=6) sin grupo control. Es relevante principalmente como concepto comparador o complementario a la hirudoterapia en el rescate de colgajos, más que como evidencia directa del tratamiento basado en sanguijuelas.

Citación

Bloodletting therapy using subcutaneous heparin and controlled scarification for venous insufficiency in free flap reconstruction.

Yalcin CE · Microsurgery, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.